Moving forward, it is crucial to standardize pSMAD2 assessment methods and to expand analyses to larger HER2+ and Triple-negative cohorts of early-stage breast cancer to fully decipher subtype-specific roles of TGF-β signaling. This evidence concerns the gene TGFB1 and breast cancer.